Ballesteros J J, Salvador M, Macías J, Honorato J, Rubio A, Azanza J R
Servicios de Urología y Microbiología, Hospital Mare de Deu de l'Esperança, Barcelona.
Rev Med Univ Navarra. 1988 Jul-Sep;32(3):135-7.
Forty patients with uncomplicated urinary tract infections were randomized to receive norfloxacin (400 mg) twice daily or trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days. The percentage of patients with bacteriological outcomes of eradication was significantly greater (p = 0.0310) with norfloxacin (90%) than the obtained percentage with trimethoprim-sulfamethoxazole (55%). The clinical response was, also, significantly better (p = 0.0012) in the norfloxacin group (100%) than in the trimethoprim-sulfamethoxazole group (55%). Two patients receiving trimethoprim-sulfamethoxazole experienced clinical side effects-gastrointestinal in nature but the treatment was not discontinued. In the norfloxacin group clinical side effects were not observed. No adverse hematological or biochemical changes were noted. From these results, we conclude that norfloxacin is more effective than trimethoprim-sulfamethoxazole in the therapy of uncomplicated urinary tract infections.
40例单纯性尿路感染患者被随机分为两组,一组每日两次服用诺氟沙星(400毫克),另一组每日两次服用甲氧苄啶 - 磺胺甲恶唑(160 - 800毫克),疗程均为10天。诺氟沙星组细菌学结果显示根除的患者百分比(90%)显著高于甲氧苄啶 - 磺胺甲恶唑组(55%)(p = 0.0310)。诺氟沙星组的临床反应(100%)也显著优于甲氧苄啶 - 磺胺甲恶唑组(55%)(p = 0.0012)。两名服用甲氧苄啶 - 磺胺甲恶唑的患者出现了临床副作用——本质上是胃肠道方面的,但治疗未中断。诺氟沙星组未观察到临床副作用。未发现不良血液学或生化变化。从这些结果来看,我们得出结论,在单纯性尿路感染的治疗中,诺氟沙星比甲氧苄啶 - 磺胺甲恶唑更有效。